PTC
PCRX icon

Petrus Trust Company’s Pacira BioSciences PCRX Stock Holding History

Petrus Trust Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,044
Closed -$492K – 706
2023
Q1 		$492K Sell
12,044
-2,530
-17% -$101K 0.06% 103
2022
Q4 		$563K Buy
+14,574
New +$709K 0.07% 69

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Petrus Trust Company's PCRX Position: Q2 2023 in Review

Petrus Trust Company sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 12,044 shares — an estimated $492K sold.

Petrus Trust Company first reported a position in PCRX in Q4 2022 and held it in 2 quarters. The position peaked at $563K in Q4 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

  • Petrus Trust Company reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
  • Petrus Trust Company sold 12,044 Pacira BioSciences shares in Q2 2023, an estimated $492K.
  • Petrus Trust Company first reported a position in Pacira BioSciences in Q4 2022 and held it in 2 quarters.
  • Petrus Trust Company's Pacira BioSciences position peaked at $563K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Petrus Trust Company's 13F filing for Q2 2023, filed 14 Aug 2023.